Galien Golden Jubilee Forum USA 2021

Oct. 28th, 2021
4:15PM – 5:30PM

In-person registrationLive broadcast registration

Mikael Dolsten, Chief Scientific Officer & President, Worldwide Research, Development and Medical, Pfizer

Robert Bradway, Chairman & CEO, Amgen
John G. Houston, President & CEO, Arvinas

Michelle McMurry-Heath, President & CEO, BIO
Jeffrey A. Spaeder, Chief Medical and Scientific Officer, and Senior Vice President, IQVIA
Michel Vounatsos, CEO & Director, Biogen Inc.


Mikael Dolsten, MD, PhD
Chief Scientific Officer and President
Worldwide Research, Development and Medical
Pfizer Inc.

Mikael leads the Worldwide Research, Development and Medical (WRDM) organization at Pfizer, which is responsible for the development of all compounds through proof of concept, and provides pharmaceutical sciences, safety and medical support to the entire R&D pipeline and all marketed products. The WRDM group contains all Pfizer research units, including Oncology, Internal Medicine, Inflammation & Immunology, Vaccines and Rare Disease, as well as the Centers for Therapeutic Innovation (CTI). Mikael has worldwide responsibility for Pfizer’s groups in medical, safety and external R&D innovation, in addition to science-based teams in pharmaceutical sciences, drug safety R&D, and large and small molecule discovery and development. Mikael is a member of the Executive Leadership Team and Pfizer’s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities.

Mikael earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden and was appointed Adjunct Professor in Tumor Immunology. He is a governor of the New York Academy of Sciences and serves on the PhRMA Research & Development Leadership Forum, the PhRMA Foundation Board of Directors, and the Board of Karyopharm Therapeutics. Mikael is a member of the Board of Overseers – Scripps Research Institute as well as a Foreign Member of The Royal Swedish Academy of Engineering Sciences. Since 2014, Mikael has co-chaired the Accelerating Medicine Partnership (AMP) with National Institutes of Health (NIH) Director Francis S. Collins. Mikael advised the Obama Administration on R&D as well as Vice President Biden’s Cancer Moonshot Initiative to accelerate cancer research.

Mikael is a named inventor on several patents and has published approximately 150 articles in international journals.

Robert Bradway
Chairman & CEO

Robert A. Bradway is Amgen’s chairman and chief executive officer, having been named to those positions in January 2013 and May 2012 respectively. He joined the company in 2006 and served as vice president of Operations Strategy, executive vice president, chief financial officer, and president and chief operating officer before assuming his current positions.

Bradway was previously a managing director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm’s banking department and corporate finance activities in Europe.

Bradway is a member of the board of directors of The Boeing Company, the W. M. Keck Foundation, the Pharmaceutical Research and Manufacturers of America (PhRMA), and the CEO Roundtable on Cancer.  He also serves on the board of trustees of the University of Southern California.

Bradway holds a bachelor’s degree in biology from Amherst College and a master’s degree in business administration from Harvard University.

Michelle McMurry-Heath
President & CEO

Dr. Michelle McMurry-Heath is the President and CEO of the Biotechnology Innovation Organization (BIO), the world’s largest biotechnology organization.  

BIO represents nearly 1,000 life sciences companies and organizations from 30 countries. The organization’s mission is to support companies that discover and deploy scientific breakthroughs that improve human heath, environmental stewardship, and sustainable agriculture.  

Since assuming leadership of BIO on June 1, 2020, Dr. McMurry-Heath has positioned BIO as a leading champion of scientific innovation and the bio-revolution, which aims to use technological breakthroughs to cure patients, protect our climate, and nourish humanity.  

A common thread throughout McMurry-Heath’s career has been her focus on broadening access to scientific progress so more patients from diverse backgrounds can benefit from cutting-edge advancements. She calls the distribution of scientific progress “the social justice issue of our age.” 

Before coming to BIO, Dr. McMurry-Heath worked at Johnson & Johnson, where she served as Global Head of Evidence Generation for Medical Device Companies and then Vice President of Global External Innovation and Global Leader for Regulatory Sciences. 

Prior to her time at J&J, Dr. McMurry-Heath was a key science policy leader in government, including serving as the associate science director of the FDA’s Center for Devices and Radiological Health. McMurry-Heath was also the founding director of the Aspen Institute’s Health, Biomedical Science, and Society Policy Program. 

McMurry-Heath received her MD/PhD from Duke’s Medical Scientist Training Program, becoming the first African American to graduate from the prestigious program. 

John G. Houston
President & CEO

Dr. Houston is President and Chief Executive Officer of Arvinas. Previously, he was the SVP of Specialty Discovery at Bristol-Myers Squibb (BMS). He spent more than 18 years at BMS in roles of increasing responsibility and had accountability for all Discovery Biology disease teams as well as various Discovery technology departments. Dr. Houston was a member of the BMS R&D Executive Leadership team and chaired the Target Portfolio Committee which had governance oversight in the discovery space. With his teams and research colleagues, he progressed over 200 compounds into early development, several of which advanced into late-stage clinical trials, and toward commercialization.

Dr. Houston has over 30 years of experience in the pharmaceutical industry. Prior to joining Bristol-Myers Squibb, he worked at Glaxo Welcome Research and Development in the UK, where he served as head of the Lead Discovery Unit. Dr. Houston currently serves on the boards of directors of NextCure, Inc., Oerth Bio, Cybrexa Therapeutics and BioCT.

Dr. Houston obtained his B.Sc. degree in Medical Microbiology from Glasgow University and obtained his Ph.D. with Professor Brian Catley in Microbial Biochemistry from Heriot-Watt University, Edinburgh. He also completed his post-doctoral studies on an MRC grant with Professor Julia Douglas at Glasgow University.

Jeffrey A. Spaeder, M.D.
Chief Medical and Scientific Officer, and Senior Vice President

Jeffrey Spaeder, M.D. is Chief Medical and Scientific Officer for IQVIA. In this role, he is the lead medical and scientific expert and is involved with the company’s oversight of scientific integrity, governance of early phase development, quality assurance, and bioethics.

Jeff has over 25 years of medical and research experience, and since 2005 has worked in the life sciences industry. Prior to joining IQVIA, Jeff worked in roles of increasing responsibility at Abbott Laboratories and Takeda in clinical development, pharmacovigilance, and medical affairs. He also was a cardiologist on the faculty of Johns Hopkins School of Medicine, where he performed novel research on mass customization of personalized healthcare and telemedicine, and he holds several patents based on his research and insights.

Jeff holds an M.D. degree from Johns Hopkins School of Medicine and completed specialty training in internal medicine at Johns Hopkins and sub-specialty training in cardiovascular medicine from Johns Hopkins and the National Heart, Lung, and Blood Institute. He holds an undergraduate degree (B.S.) in Engineering Science from The Pennsylvania State University and a Master’s in Business Administration (M.B.A.) with a concentration in Finance from Northwestern University’s Kellogg School of Management.

Michel Vounatsos
CEO & Director
Biogen Inc.

Michel Vounatsos has been Chief Executive Officer (CEO) of Biogen and a member of its Board of Directors since January 2017. He joined the company in 2016 as Executive Vice President, Chief Commercial Officer.
Under Mr. Vounatsos’ direction, Biogen is pursuing its strategy as a leader in neuroscience as well as adjacent therapeutic areas, underpinned by the belief that neurological diseases and treatment strategies are interconnected.
Prior to joining Biogen, Mr. Vounatsos had a 20-year career at Merck and has additionally held management positions at Ciba-Geigy.
Michel received his C.S.C.T. certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.